NEW YORK (GenomeWeb News) – BG Medicine said today that the Centers for Medicare and Medicaid Services have published the final determination of the 2014 Medicare national limitation amount for the company's galectin-3 test, arriving at a price of $30.01.

This is an increase over the test's 2013 national limitation of $17.80, and represents a win for BG Medicine, which had petitioned CMS for reconsideration of the 2013 determination.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: method to detect single-nucleotide and copy-number alterations in single cells from archival tissue, and more.

China has announced new rules governing the use of stem cell treatments, Nature News reports.

Wired's Sarah Zhang expresses frustration as a microbiome study of homes uncovers expected bacteria.

A database containing genome sequences from strains of foodborne pathogens may enable regulators and companies to quickly identify outbreak sources, Reuters reports.